Pearl Steinzor

Amy S. Paller, MD, chair of the department of dermatology at Feinberg School of Medicine at Northwestern University, discussed using systemic therapies to treat children with atopic dermatitis (AD).

AnaptysBio's senior vice president of research, Martin Dahl, PhD, discusses therapeutic strategies and pathophysiological approaches to treating patients with atopic dermatitis (AD).

Jeff Stark, MD, vice president and head of medical immunology, UCB, shares phase 3 study results of bimekizumab-bkzx given for up to 48 weeks in patients with moderate to severe hidradenitis suppurativa (HS).

In patients with moderate to severe atopic dermatitis, nemolizumab demonstrated good durability of response, explained Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences.

Monica Li, MD, medical and cosmetic dermatologist and clinical assistant professor, University of British Columbia, discusses how microneedling can address both aesthetic and medical dermatological needs across different skin types.

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses what makes a dermatology practice successful and the challenges that come with running a practice.

There are key factors to consider when selecting which patients with atopic dermatitis (AD) are suitable candidates for oral Janus kinase (JAK) inhibitors, explained Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research.

Amy S. Paller, MD, chair of dermatology, Feinberg School of Medicine at Northwestern University, discusses aspects of this year's American Academy of Dermatology (AAD) conference she is most excited about.

Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.

Air pollution exposure during the first 3 years of life was associated with asthma incidence, according to one study.

Improvement across all asthma control parameters was achieved after 12 months of biologic treatment, according to one study.

While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.

Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.

A nationwide analysis reveals a significant drop in cancer diagnoses, highlighting an urgent need for a catch-up in screening efforts.

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

Changing High-Risk Asthma in Memphis through Partnerships significantly decreased health care use related to asthma among children.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute, shares her thoughts on future directions in value-based oncology care and research.

Coverage from the Institute for Value-Based Medicine event in Tampa, Florida, with Moffitt Cancer Center.

Coverage in the February 2024 issue of Evidence-Based Oncology.

Children treated with dupilumab showed improved lung function compared with placebo group, according to one study.

Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, discusses methods for identifying patients with indolent systemic mastocyctosis (ISM) using health claims data.

It is important to study the safety of targeted therapies in populations at increased risk of skin cancer, according to the researchers.

Researchers have identified a surge in breast cancer rates among young women and racial disparities across age groups.

Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis.

These modifiable environmental factors were independently associated with asthma severity, according to one study.

Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab.

A Mendelian randomization analysis supported an increasing causal relationship between asthma and lung cancer risk, particularly in smokers and lung squamous cell carcinoma.

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the complex landscape of proposed health care rules, and the potential impact of CMS' Advancing Interoperability and Prior Authorizations Rule.